Iritor Tablet 20 mg (Atorvastatin Calcium Hydrate)
Atorvastatin Calcium Hydrate 21.7mg
Tablet · Prescription medication
Introbiopharma Co., Ltd.
MFDS item code 201900715 · Approved 2019.01.30
This product's status changed to Expired on 2024.01.30. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of hyperlipidemia (including familial hypercholesterolemia in children); prevention of cardiovascular events (such as myocardial infarction and stroke)
This medication helps reduce the risk of myocardial infarction, stroke, the need for vascular interventions, and angina in adults with cardiovascular disease risk factors and in patients with Type 2 diabetes. Especially for patients with coronary artery disease, it effectively reduces the risk of hospitalization due to myocardial infarction, stroke, and congestive heart failure. Additionally, this medication lowers cholesterol and triglyceride levels in patients with primary and mixed hyperlipidemia, while increasing the level of good cholesterol (HDL) to improve blood lipid status. Furthermore, it is used to effectively manage lipid levels in pediatric patients with familial hypercholesterolemia aged 10 and above to control the risk of heart disease. Therefore, this medication is very useful for the prevention of cardiovascular diseases and the treatment of hyperlipidemia.
Patients receiving atorvastatin should follow a standard cholesterol-lowering diet before and during treatment. The drug may be taken at any time of day, with or without food. 1. Hyperlipidemia The recommended initial dose is 10 mg of atorvastatin once daily. However, patients requiring a greater reduction in LDL cholesterol may start with 20 mg or 40 mg once daily (the 40 mg dose is only for patients requiring a reduction in LDL cholesterol of 45% or more). This drug is administered at doses ranging from 10 ~ 80 mg once daily. The initial and maintenance doses should be individualized according to the patient's characteristics, taking into consideration treatment goals and response. Lipid levels should be analyzed within 2 ~ 4 weeks of starting treatment and/or after dose titration, and the dose should be adjusted accordingly. Because the treatment goal is to lower LDL cholesterol, LDL cholesterol levels are recommended for use when initiating treatment and evaluating response. However, if LDL cholesterol levels are unavailable, total cholesterol levels should be used to monitor treatment response. Patients with homozygous familial hypercholesterolemia The dose of this drug is 10 ~ 80 mg once daily. It is administered in combination with other lipid-lowering treatments (e.g., LDL apheresis), or when such treatments are not available. ○ Patients with renal impairment: Renal disease does not affect the plasma concentration of atorvastatin or its LDL cholesterol-lowering effect; therefore, no dosage adjustment is necessary. ○ Elderly patients: The efficacy and safety in patients aged 70 years or older are generally similar to those in the general adult patient population.
Pediatric patients with heterozygous familial hypercholesterolemia (10 ~ 17 years): The recommended initial dose is 10 mg of this drug once daily, and the recommended maximum dose is 20 mg daily (there are no clinical data on doses higher than 20 mg in pediatric patients). The dose should be adjusted as appropriate according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer.
This medication may cause muscle-related symptoms, so if there is severe muscle pain or weakness, or significantly elevated creatine kinase levels, the patient should immediately discontinue use and consult a physician. Patients with liver function problems may experience worsened liver function when taking this medication, so it should not be used if there is liver disease or abnormally high liver enzyme levels. Women who are pregnant, capable of becoming pregnant, or breastfeeding should not take this medication, and women of childbearing age should use appropriate contraception while taking it. Children, especially those under 10 years old, should preferably not take this medication, and for children over 10 years old, safety and efficacy during long-term use have not been sufficiently verified. This medication may cause increased or decreased blood concentration when taken with certain drugs, so patients should inform their doctor or pharmacist if they are taking other medications. Particularly, the risk of muscle-related side effects may increase when used with strong CYP3A4 inhibitors, certain antibiotics, antifungal medications, HIV treatments, and some hyperlipidemia treatments. If symptoms of liver dysfunction appear (e.g., jaundice, extreme fatigue, nausea, vomiting), the patient should immediately stop taking this medication and consult healthcare professionals. Elderly patients, patients with renal impairment, and alcoholic patients should be monitored carefully for side effects when taking this medication. During treatment with this medication, if symptoms such as muscle pain, weakness, or fever occur, the patient should immediately seek medical attention, and blood tests may be necessary to check for muscle damage. This medication should be avoided with grapefruit juice as it may increase blood concentration.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is best to maintain a storage temperature between 1 to 30 degrees Celsius.
White round film-coated tablets
Bottle pack - 30 tablets/bottle, Bottle pack - 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Atorvastatin Calcium Hydrate 21.7mg
Tablet · Prescription medication
Introbiopharma Co., Ltd.

Atorvastatin Calcium Trihydrate 21.7mg
Tablet · Prescription medication
Viatris Korea Co., Ltd.

Atorvastatin Calcium Trihydrate 43.4mg
Tablet · Prescription medication
Viatris Korea Co., Ltd.

Atorvastatin Calcium Trihydrate 10.85mg
Tablet · Prescription medication
Viatris Korea Co., Ltd.

Atorvastatin Calcium Trihydrate 10.85mg
Tablet · Prescription medication
Kyungdong Pharmaceutical Co., Ltd.

Atorvastatin Calcium Trihydrate 21.69mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.

Atorvastatin Calcium Trihydrate 21.69mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Atorvastatin Calcium Trihydrate 10.845mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.